Ocular Therapeutix reports FY2024 revenue $63.7M, net loss $(193.5)M; updates AXPAXLI registrational program

OCULAR THERAPEUTIX, INC

Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.
Cash balance $392.1M as of Dec 31, 2024; expected to fund operations into 2028; no plans to raise additional capital in 2025.
SOL-1 Phase 3 wet AMD trial amended to include re-dosing at Weeks 52 and 76; Week 36 primary endpoint data expected in 1Q 2026.
SOL-R trial size reduced from 825 to 555 subjects due to re-dosing inclusion in SOL-1; non-inferiority margin -4.5 letters BCVA vs aflibercept.
FDA feedback on AXPAXLI clinical trial design for NPDR and DME anticipated in 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.